803 related articles for article (PubMed ID: 2406902)
1. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
Daley GQ; Van Etten RA; Baltimore D
Science; 1990 Feb; 247(4944):824-30. PubMed ID: 2406902
[TBL] [Abstract][Full Text] [Related]
2. Blast crisis in a murine model of chronic myelogenous leukemia.
Daley GQ; Van Etten RA; Baltimore D
Proc Natl Acad Sci U S A; 1991 Dec; 88(24):11335-8. PubMed ID: 1763047
[TBL] [Abstract][Full Text] [Related]
3. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias.
Honda H; Oda H; Suzuki T; Takahashi T; Witte ON; Ozawa K; Ishikawa T; Yazaki Y; Hirai H
Blood; 1998 Mar; 91(6):2067-75. PubMed ID: 9490692
[TBL] [Abstract][Full Text] [Related]
4. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein.
Daley GQ; Baltimore D
Proc Natl Acad Sci U S A; 1988 Dec; 85(23):9312-6. PubMed ID: 3143116
[TBL] [Abstract][Full Text] [Related]
5. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.
Kelliher MA; McLaughlin J; Witte ON; Rosenberg N
Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6649-53. PubMed ID: 2204061
[TBL] [Abstract][Full Text] [Related]
6. Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice.
Mizuno T; Yamasaki N; Miyazaki K; Tazaki T; Koller R; Oda H; Honda ZI; Ochi M; Wolff L; Honda H
Oncogene; 2008 May; 27(24):3465-74. PubMed ID: 18193087
[TBL] [Abstract][Full Text] [Related]
7. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
[TBL] [Abstract][Full Text] [Related]
8. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
Zhang X; Ren R
Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
[TBL] [Abstract][Full Text] [Related]
9. Enhanced expression of p210BCR/ABL and aberrant expression of Zfp423/ZNF423 induce blast crisis of chronic myelogenous leukemia.
Miyazaki K; Yamasaki N; Oda H; Kuwata T; Kanno Y; Miyazaki M; Komeno Y; Kitaura J; Honda Z; Warming S; Jenkins NA; Copeland NG; Kitamura T; Nakamura T; Honda H
Blood; 2009 May; 113(19):4702-10. PubMed ID: 19234145
[TBL] [Abstract][Full Text] [Related]
10. Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl.
Laneuville P; Sun G; Timm M; Vekemans M
Blood; 1992 Oct; 80(7):1788-97. PubMed ID: 1327283
[TBL] [Abstract][Full Text] [Related]
11. Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth.
Skorski T; Kanakaraj P; Ku DH; Nieborowska-Skorska M; Canaani E; Zon G; Perussia B; Calabretta B
J Exp Med; 1994 Jun; 179(6):1855-65. PubMed ID: 8195713
[TBL] [Abstract][Full Text] [Related]
12. Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
Okabe M; Uehara Y; Miyagishima T; Itaya T; Tanaka M; Kuni-Eda Y; Kurosawa M; Miyazaki T
Blood; 1992 Sep; 80(5):1330-8. PubMed ID: 1515646
[TBL] [Abstract][Full Text] [Related]
13. Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line.
Carlesso N; Griffin JD; Druker BJ
Oncogene; 1994 Jan; 9(1):149-56. PubMed ID: 8302574
[TBL] [Abstract][Full Text] [Related]
14. Expression of p210bcr/abl by metallothionein promoter induced T-cell leukemia in transgenic mice.
Honda H; Fujii T; Takatoku M; Mano H; Witte ON; Yazaki Y; Hirai H
Blood; 1995 May; 85(10):2853-61. PubMed ID: 7537982
[TBL] [Abstract][Full Text] [Related]
15. Model mice for BCR/ABL-positive leukemias.
Honda H; Hirai H
Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
[TBL] [Abstract][Full Text] [Related]
16. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.
Maxwell SA; Kurzrock R; Parsons SJ; Talpaz M; Gallick GE; Kloetzer WS; Arlinghaus RB; Kouttab NM; Keating MJ; Gutterman JU
Cancer Res; 1987 Mar; 47(6):1731-9. PubMed ID: 2434223
[TBL] [Abstract][Full Text] [Related]
17. Establishment, characterization, and chromosomal analysis of new leukemic cell lines derived from MT/p210bcr/abl transgenic mice.
Honda H; Ohno S; Takahashi T; Takatoku M; Yazaki Y; Hirai H
Exp Hematol; 1998 Mar; 26(3):188-97. PubMed ID: 9502614
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
[TBL] [Abstract][Full Text] [Related]
19. Crk-associated substrate lymphocyte type regulates myeloid cell motility and suppresses the progression of leukemia induced by p210Bcr/Abl.
Seo S; Nakamoto T; Takeshita M; Lu J; Sato T; Suzuki T; Kamikubo Y; Ichikawa M; Noda M; Ogawa S; Honda H; Oda H; Kurokawa M
Cancer Sci; 2011 Dec; 102(12):2109-17. PubMed ID: 21848808
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
